Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

January 31, 2017

Conditions
Relapsed Multiple MyelomaEnd-stage Renal Disease
Interventions
DRUG

Carfilzomib

Carfilzomib was administered by IV injection.

Trial Locations (13)

Unknown

Karmanos Cancer Institute, Detroit

North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital, Lake Success

Gabrail Cancer Center, Canton

Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic, Nashville

Baylor Charles A. Sammons Cancer Center, Dallas

UT Southwestern Medical Center, Dallas

Royal Prince Alfred Hospital, Camperdown

Royal Brisbane and Women's Hospital, Herston

Monash Health, Monash Medical Centre, Clayton

St. Vincent's Hospital Melbourne, Fitzroy

The Alfred Hospital, Malignant Haematology and Stem Cell Transplant Department, Melbourne

QEII Health Sciences Centre, Halifax

Sir Mortimer B. Davis-Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY